|Bid||0.00 x 1300|
|Ask||0.00 x 1000|
|Day's Range||26.02 - 27.46|
|52 Week Range||24.67 - 156.82|
|Beta (5Y Monthly)||0.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 25, 2022 - Oct 31, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.68|
A rising tide is lifting all boats -- including one with "Teladoc" written on the side of it.
Few stocks were as popular at the height of the pandemic as Teladoc Health (NYSE: TDOC). The market leader in telehealth -- a rapidly growing industry on track to hit $636 billion by 2028 -- Teladoc had an incredibly appealing business model for investors seeking to capitalize on the stay-safe-at-home and work-from-home booms. Over the last year, as many popular growth stocks have fallen out of favor, and much of the world has reopened and returned to a sense of normalcy, Teladoc has followed the path of so many work-from-home stocks.
Arguably no stock has gone from hero to zero more dramatically than telehealth company Teladoc Health (NYSE: TDOC). The company's growth surged during COVID-19, but its blockbuster acquisition of Livongo has seemingly blown up in its face. To be frank, Teladoc messed up.